Menu

Theranos Goes Under

The discredited blood-testing company announced its decision to close in a company-wide email.

Sep 5, 2018
Sukanya Charuchandra
Elizabeth Holmes

The blood-testing company Theranos will be dissolving and returning its remaining cash (approximately $5 million) to its creditors, reports The Wall Street Journal

The troubled company’s CEO and general counsel, David Taylor, made the declaration in an email to shareholders and said, “I write with difficult news about the future of the Company.” The firm’s remaining employees worked their last day on August 31. 

The move comes after Theranos failed to secure a buyer or further investments and ended up breaking the terms of its $65 million loan from Fortress Investment Group. By brokering of a deal with the investment firm, Theranos gets to consolidate its leftover money in a trust for creditors that might take between six to 12 months to process. The email states, “Because the Company’s cash is not nearly sufficient to pay all of its creditors in full, there will be no distributions to shareholders.” 

Three months ago, Theranos’s founder Elizabeth Holmes and former CEO Ramesh Balwani faced criminal charges for committing a multimillion-dollar fraud against investors, doctors, and patients. According to Financial Times, Holmes resigned immediately following the indictment. Among the company’s most well-known investors were Rupert Murdoch, Walmart’s Walton family, and the family of Betsy DeVos.

The criminal charges are in addition to the Securities and Exchange Commission’s civil charges against Theranos, Holmes, and Balwani for defrauding investors of $700 million, a case that Balwani is still fighting. 

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.